Neurofibromatoza typu 1 – Rokowania, prognozy i postęp choroby

Neurofibromatoza typu 1
Rokowania, prognozy i postęp choroby

Neurofibromatoza typu 1 (NF1) jest autosomalnie dominującym zaburzeniem genetycznym, charakteryzującym się dużą heterogennością fenotypową i zmiennym rokowaniem zależnym od nasilenia choroby, obecności nowotworów złośliwych oraz stopnia deformacji. Mimo że łagodne postaci NF1 nie wpływają znacząco na oczekiwaną długość życia, to u pacjentów z umiarkowanymi i ciężkimi objawami obserwuje się pogorszenie jakości życia. Kluczowymi czynnikami ryzyka śmiertelności są guzy mózgu oraz złośliwe nowotwory osłonek nerwów obwodowych (MPNST), które występują u 8-13% pacjentów i wiążą się z 5-letnim wskaźnikiem przeżycia na poziomie 44-55%. Dodatkowo, guzy ośrodkowego układu nerwowego zwiększają ryzyko wtórnych nowotworów i powikłań naczyniowych, a rak piersi związany z NF1 charakteryzuje się niskim 5-letnim wskaźnikiem przeżycia i wysoką śmiertelnością.

Prognoza w neurofibromatozie typu 1 (NF1)

Oczekiwana długość życia
Czynniki pogarszające rokowanie
Inne czynniki wpływające na rokowanie
Monitorowanie i wczesne wykrywanie
Postępy w diagnostyce
Znaczenie wczesnej interwencji
Kolejne rozdziały

Prognoza w neurofibromatozie typu 1 (NF1)

Neurofibromatoza typu 1 (NF1) to zaburzenie autosomalnie dominujące spowodowane mutacjami w genie NF1, zwykle diagnozowane we wczesnym dzieciństwie i charakteryzujące się znaczną heterogennością fenotypową¹. Rokowanie u pacjentów z NF1 jest zróżnicowane i zależy od kilku kluczowych czynników, w tym nasilenia choroby, obecności nowotworów złośliwych oraz stopnia deformacji².

Oczekiwana długość życia

Ogólnie rzecz biorąc, NF1 nie wpływa bezpośrednio na oczekiwaną długość życia, jeśli objawy są łagodne. Większość pacjentów może oczekiwać przeciętnej długości życia³. Osoby z łagodną postacią choroby mogą mieć rozsądną oczekiwaną długość życia, natomiast pacjenci z umiarkowaną do ciężkiej postacią choroby mają gorszą jakość życia⁴.

Czynniki pogarszające rokowanie

Rokowanie w NF1 zależy od rodzaju i lokalizacji guzów, obecności powikłań oraz rozwoju nowotworów złośliwych⁵. Do głównych czynników wpływających na śmiertelność wśród pacjentów z NF1 należą guzy mózgu i złośliwe nowotwory osłonek nerwów obwodowych (MPNST)⁶.

Nowotwory złośliwe osłonek nerwów obwodowych (MPNST) – występują u 8-13% pacjentów z NF1 i wiążą się z gorszym rokowaniem. Pacjenci, u których rozwijają się MPNST, mają 5-letni wskaźnik przeżycia wynoszący około 44-55%⁷.
Guzy ośrodkowego układu nerwowego – pacjenci z guzami OUN są narażeni na zwiększone ryzyko wystąpienia wtórnych nowotworów złośliwych, wyższą śmiertelność i powikłania naczyniowe⁸.
Rak piersi związany z NF1 – kobiety z rakiem piersi związanym z NF1 mają niski 5-letni wskaźnik przeżycia i wysoką śmiertelność⁹.

¹⁰¹¹

Inne czynniki wpływające na rokowanie

Poza bezpośrednim zagrożeniem życia, NF1 może znacząco wpływać na jakość życia pacjentów. Badanie kohortowe 2467 osób z duńskiej bazy danych RAREDIS (1995-2013) wykazało zwiększone ryzyko hospitalizacji, chorób psychicznych, słabych wyników w nauce, problemów w związkach, poronień i martwych urodzeń, gorszej jakości życia oraz zwiększonej zależności od innych¹².

Inne czynniki wpływające na rokowanie obejmują obecność zaburzeń poznawczych, nieprawidłowości szkieletowych i innych powikłań związanych z neurofibromatozą typu 1¹³. Powikłania, choć rzadsze, mogą wpływać na rokowanie, szczególnie jeśli pacjent ma liczne guzy, których nie można bezpiecznie usunąć chirurgicznie, lub jeśli guzy rozwijają się w kierunku nowotworów złośliwych¹⁴.

Monitorowanie i wczesne wykrywanie

Wczesne wykrycie i regularna obserwacja mają kluczowe znaczenie dla skutecznego zarządzania i zmniejszenia ryzyka raka u pacjentów z neurofibromatozą typu 1¹⁵. Zaleca się przeprowadzanie seryjnej oceny za pomocą całościowego obrazowania metodą rezonansu magnetycznego (WBMRI), dostosowanej do stanu klinicznego i specyficznych objawów NF1¹⁶.

Zrozumienie ryzyka nowotworowego u pacjentów z neurofibromatozą typu 1 ma kluczowe znaczenie dla wczesnego wykrywania, monitorowania i leczenia, z celem poprawy wyników i jakości życia pacjentów¹⁷.

Postępy w diagnostyce

Mimo postępów w sekwencjonowaniu nowej generacji (NGS), proces diagnostyczny pozostaje wyzwaniem ze względu na złożoność genu, wysokie obciążenie mutacjami i częste identyfikowanie wariantów o niepewnym znaczeniu (VUS). Integracja metodologii sztucznej inteligencji (AI) oferuje znaczny potencjał w zakresie poprawy precyzji diagnostycznej, umożliwienia wczesnej interwencji i wsparcia podejść medycyny spersonalizowanej¹⁸.

Jednak kluczowe wyzwania pozostają, w tym elfekt błędu algorytmicznego, ograniczona różnorodność danych i potrzeba walidacji funkcjonalnej. Ciągłe udoskonalanie i walidacja kliniczna tych narzędzi są niezbędne, aby zapewnić ich skuteczne wdrożenie i sprawiedliwe wykorzystanie w diagnostyce NF1¹⁹.

Znaczenie wczesnej interwencji

Rokowanie w neurofibromatozie typu 1 jest zróżnicowane i zależne od wielu czynników. Chociaż większość pacjentów z łagodną postacią choroby może oczekiwać przeciętnej długości życia, obecność określonych powikłań – szczególnie nowotworów złośliwych – znacząco pogarsza rokowanie. Wczesne wykrywanie i leczenie tych nowotworów złośliwych ma kluczowe znaczenie dla poprawy wyników²⁰.

Regularne monitorowanie, szczególnie u pacjentów z czynnikami ryzyka rozwoju nowotworów złośliwych, może przyczynić się do poprawy rokowania poprzez wczesne wykrywanie i leczenie potencjalnie zagrażających życiu powikłań²¹²².

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1 Genes | An Open Access Journal from MDPI
https://www.mdpi.com/journal/genes
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder caused by mutations in the NF1 gene, typically diagnosed during early childhood and characterized by significant phenotypic heterogeneity. […] Despite advancements in next-generation sequencing (NGS), the diagnostic process remains challenging due to the geneâs complexity, high mutational burden, and frequent identification of variants of uncertain significance (VUS). This review explores the emerging role of artificial intelligence (AI) in enhancing NF1 variant detection, classification, and interpretation. […] The integration of AI methodologies offers substantial potential to improve diagnostic precision, enable early intervention, and support personalized medicine approaches. However, key challenges remain, including algorithmic bias, limited data diversity, and the need for functional validation. Ongoing refinement and clinical validation of these tools are essential to ensure their effective implementation and equitable use in NF1 diagnostics.
#2 Neurofibromatosis Type 1 – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK459358/
The outlook for patients with NF-1 is guarded and depends on the severity of the disease, the presence of malignancy, and the extent of the deformity. Those with mild disease can have a reasonable life expectancy, but those with moderate to severe disease have a poor quality of life. […] Women with NF-1-related breast cancer have a poor 5-year survival rate and high mortality. […] Patients with central nervous system tumors are at increased risk for secondary malignancies, mortality, and vascular complications. […] Malignant peripheral nerve sheath tumors in association with NF-1 have poor overall survival. […] The primary contributing variable to mortality among patients with NF1 includes brain tumors and MPNSTs. […] Serial evaluation with WBMRI should be assessed based on the clinical and NF1 domains. […] The cohort of 2467 individuals from the Denmark RAREDIS Database from (1995-2013) was observed to have increased odds for the risk of hospitalizations, psychiatric illnesses, poor academic performances, poor relationship, abortions and stillbirths, poor quality of life, and increased dependency.
#3 Neurofibromatosis Type 1 (NF1): Symptoms & Treatment
https://my.clevelandclinic.org/health/diseases/14422-neurofibromatosis-type-1-nf1
Overall, NF1 doesnt directly affect your life expectancy if your symptoms are mild. Most people experience an average life expectancy. […] Complications, while less common, may affect your prognosis, especially if you have numerous tumors that cant safely be surgically removed or if your tumors develop into cancer.
#4 Neurofibromatosis Type 1 – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK459358/
The outlook for patients with NF-1 is guarded and depends on the severity of the disease, the presence of malignancy, and the extent of the deformity. Those with mild disease can have a reasonable life expectancy, but those with moderate to severe disease have a poor quality of life. […] Women with NF-1-related breast cancer have a poor 5-year survival rate and high mortality. […] Patients with central nervous system tumors are at increased risk for secondary malignancies, mortality, and vascular complications. […] Malignant peripheral nerve sheath tumors in association with NF-1 have poor overall survival. […] The primary contributing variable to mortality among patients with NF1 includes brain tumors and MPNSTs. […] Serial evaluation with WBMRI should be assessed based on the clinical and NF1 domains. […] The cohort of 2467 individuals from the Denmark RAREDIS Database from (1995-2013) was observed to have increased odds for the risk of hospitalizations, psychiatric illnesses, poor academic performances, poor relationship, abortions and stillbirths, poor quality of life, and increased dependency.
#5 Cancer Risk in Patients With Neurofibromatosis Type 1 – Diagnosis & Disease Information
https://www.cancertherapyadvisor.com/ddi/cancer-risk-in-patients-with-neurofibromatosis-type-1/
The prognosis for neurofibromatosis type 1 depends on the type and location of tumors, the presence of complications, and the development of malignant tumors. Although most people with neurofibromatosis type 1 have an average life expectancy, those who develop MPNSTs (8% to 13%) or other cancers face a more challenging prognosis. Malignant peripheral nerve sheath tumors are aggressive and patients who develop them have a 5-year survival rate of approximately 44% to 55%. Early detection and treatment of these malignancies are critical for improving outcomes. Other factors affecting the prognosis include the presence of cognitive impairments, skeletal abnormalities, and other complications related to neurofibromatosis type 1. […] Understanding the cancer risk of patients with neurofibromatosis type 1 is crucial for early detection, monitoring, and management, with the goal of improving patient outcomes and quality of life. […] Early detection and regular surveillance are paramount for effective management and reduction of cancer risk in neurofibromatosis type 1 patients.
#6 Neurofibromatosis Type 1 – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK459358/
The outlook for patients with NF-1 is guarded and depends on the severity of the disease, the presence of malignancy, and the extent of the deformity. Those with mild disease can have a reasonable life expectancy, but those with moderate to severe disease have a poor quality of life. […] Women with NF-1-related breast cancer have a poor 5-year survival rate and high mortality. […] Patients with central nervous system tumors are at increased risk for secondary malignancies, mortality, and vascular complications. […] Malignant peripheral nerve sheath tumors in association with NF-1 have poor overall survival. […] The primary contributing variable to mortality among patients with NF1 includes brain tumors and MPNSTs. […] Serial evaluation with WBMRI should be assessed based on the clinical and NF1 domains. […] The cohort of 2467 individuals from the Denmark RAREDIS Database from (1995-2013) was observed to have increased odds for the risk of hospitalizations, psychiatric illnesses, poor academic performances, poor relationship, abortions and stillbirths, poor quality of life, and increased dependency.
#7 Cancer Risk in Patients With Neurofibromatosis Type 1 – Diagnosis & Disease Information
https://www.cancertherapyadvisor.com/ddi/cancer-risk-in-patients-with-neurofibromatosis-type-1/
The prognosis for neurofibromatosis type 1 depends on the type and location of tumors, the presence of complications, and the development of malignant tumors. Although most people with neurofibromatosis type 1 have an average life expectancy, those who develop MPNSTs (8% to 13%) or other cancers face a more challenging prognosis. Malignant peripheral nerve sheath tumors are aggressive and patients who develop them have a 5-year survival rate of approximately 44% to 55%. Early detection and treatment of these malignancies are critical for improving outcomes. Other factors affecting the prognosis include the presence of cognitive impairments, skeletal abnormalities, and other complications related to neurofibromatosis type 1. […] Understanding the cancer risk of patients with neurofibromatosis type 1 is crucial for early detection, monitoring, and management, with the goal of improving patient outcomes and quality of life. […] Early detection and regular surveillance are paramount for effective management and reduction of cancer risk in neurofibromatosis type 1 patients.
#8 Neurofibromatosis Type 1 – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK459358/
The outlook for patients with NF-1 is guarded and depends on the severity of the disease, the presence of malignancy, and the extent of the deformity. Those with mild disease can have a reasonable life expectancy, but those with moderate to severe disease have a poor quality of life. […] Women with NF-1-related breast cancer have a poor 5-year survival rate and high mortality. […] Patients with central nervous system tumors are at increased risk for secondary malignancies, mortality, and vascular complications. […] Malignant peripheral nerve sheath tumors in association with NF-1 have poor overall survival. […] The primary contributing variable to mortality among patients with NF1 includes brain tumors and MPNSTs. […] Serial evaluation with WBMRI should be assessed based on the clinical and NF1 domains. […] The cohort of 2467 individuals from the Denmark RAREDIS Database from (1995-2013) was observed to have increased odds for the risk of hospitalizations, psychiatric illnesses, poor academic performances, poor relationship, abortions and stillbirths, poor quality of life, and increased dependency.
#9 Neurofibromatosis Type 1 – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK459358/
The outlook for patients with NF-1 is guarded and depends on the severity of the disease, the presence of malignancy, and the extent of the deformity. Those with mild disease can have a reasonable life expectancy, but those with moderate to severe disease have a poor quality of life. […] Women with NF-1-related breast cancer have a poor 5-year survival rate and high mortality. […] Patients with central nervous system tumors are at increased risk for secondary malignancies, mortality, and vascular complications. […] Malignant peripheral nerve sheath tumors in association with NF-1 have poor overall survival. […] The primary contributing variable to mortality among patients with NF1 includes brain tumors and MPNSTs. […] Serial evaluation with WBMRI should be assessed based on the clinical and NF1 domains. […] The cohort of 2467 individuals from the Denmark RAREDIS Database from (1995-2013) was observed to have increased odds for the risk of hospitalizations, psychiatric illnesses, poor academic performances, poor relationship, abortions and stillbirths, poor quality of life, and increased dependency.
#10 Neurofibromatosis Type 1 – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK459358/
The outlook for patients with NF-1 is guarded and depends on the severity of the disease, the presence of malignancy, and the extent of the deformity. Those with mild disease can have a reasonable life expectancy, but those with moderate to severe disease have a poor quality of life. […] Women with NF-1-related breast cancer have a poor 5-year survival rate and high mortality. […] Patients with central nervous system tumors are at increased risk for secondary malignancies, mortality, and vascular complications. […] Malignant peripheral nerve sheath tumors in association with NF-1 have poor overall survival. […] The primary contributing variable to mortality among patients with NF1 includes brain tumors and MPNSTs. […] Serial evaluation with WBMRI should be assessed based on the clinical and NF1 domains. […] The cohort of 2467 individuals from the Denmark RAREDIS Database from (1995-2013) was observed to have increased odds for the risk of hospitalizations, psychiatric illnesses, poor academic performances, poor relationship, abortions and stillbirths, poor quality of life, and increased dependency.
#11 Cancer Risk in Patients With Neurofibromatosis Type 1 – Diagnosis & Disease Information
https://www.cancertherapyadvisor.com/ddi/cancer-risk-in-patients-with-neurofibromatosis-type-1/
The prognosis for neurofibromatosis type 1 depends on the type and location of tumors, the presence of complications, and the development of malignant tumors. Although most people with neurofibromatosis type 1 have an average life expectancy, those who develop MPNSTs (8% to 13%) or other cancers face a more challenging prognosis. Malignant peripheral nerve sheath tumors are aggressive and patients who develop them have a 5-year survival rate of approximately 44% to 55%. Early detection and treatment of these malignancies are critical for improving outcomes. Other factors affecting the prognosis include the presence of cognitive impairments, skeletal abnormalities, and other complications related to neurofibromatosis type 1. […] Understanding the cancer risk of patients with neurofibromatosis type 1 is crucial for early detection, monitoring, and management, with the goal of improving patient outcomes and quality of life. […] Early detection and regular surveillance are paramount for effective management and reduction of cancer risk in neurofibromatosis type 1 patients.
#12 Neurofibromatosis Type 1 – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK459358/
The outlook for patients with NF-1 is guarded and depends on the severity of the disease, the presence of malignancy, and the extent of the deformity. Those with mild disease can have a reasonable life expectancy, but those with moderate to severe disease have a poor quality of life. […] Women with NF-1-related breast cancer have a poor 5-year survival rate and high mortality. […] Patients with central nervous system tumors are at increased risk for secondary malignancies, mortality, and vascular complications. […] Malignant peripheral nerve sheath tumors in association with NF-1 have poor overall survival. […] The primary contributing variable to mortality among patients with NF1 includes brain tumors and MPNSTs. […] Serial evaluation with WBMRI should be assessed based on the clinical and NF1 domains. […] The cohort of 2467 individuals from the Denmark RAREDIS Database from (1995-2013) was observed to have increased odds for the risk of hospitalizations, psychiatric illnesses, poor academic performances, poor relationship, abortions and stillbirths, poor quality of life, and increased dependency.
#13 Cancer Risk in Patients With Neurofibromatosis Type 1 – Diagnosis & Disease Information
https://www.cancertherapyadvisor.com/ddi/cancer-risk-in-patients-with-neurofibromatosis-type-1/
The prognosis for neurofibromatosis type 1 depends on the type and location of tumors, the presence of complications, and the development of malignant tumors. Although most people with neurofibromatosis type 1 have an average life expectancy, those who develop MPNSTs (8% to 13%) or other cancers face a more challenging prognosis. Malignant peripheral nerve sheath tumors are aggressive and patients who develop them have a 5-year survival rate of approximately 44% to 55%. Early detection and treatment of these malignancies are critical for improving outcomes. Other factors affecting the prognosis include the presence of cognitive impairments, skeletal abnormalities, and other complications related to neurofibromatosis type 1. […] Understanding the cancer risk of patients with neurofibromatosis type 1 is crucial for early detection, monitoring, and management, with the goal of improving patient outcomes and quality of life. […] Early detection and regular surveillance are paramount for effective management and reduction of cancer risk in neurofibromatosis type 1 patients.
#14 Neurofibromatosis Type 1 (NF1): Symptoms & Treatment
https://my.clevelandclinic.org/health/diseases/14422-neurofibromatosis-type-1-nf1
Overall, NF1 doesnt directly affect your life expectancy if your symptoms are mild. Most people experience an average life expectancy. […] Complications, while less common, may affect your prognosis, especially if you have numerous tumors that cant safely be surgically removed or if your tumors develop into cancer.
#15 Cancer Risk in Patients With Neurofibromatosis Type 1 – Diagnosis & Disease Information
https://www.cancertherapyadvisor.com/ddi/cancer-risk-in-patients-with-neurofibromatosis-type-1/
The prognosis for neurofibromatosis type 1 depends on the type and location of tumors, the presence of complications, and the development of malignant tumors. Although most people with neurofibromatosis type 1 have an average life expectancy, those who develop MPNSTs (8% to 13%) or other cancers face a more challenging prognosis. Malignant peripheral nerve sheath tumors are aggressive and patients who develop them have a 5-year survival rate of approximately 44% to 55%. Early detection and treatment of these malignancies are critical for improving outcomes. Other factors affecting the prognosis include the presence of cognitive impairments, skeletal abnormalities, and other complications related to neurofibromatosis type 1. […] Understanding the cancer risk of patients with neurofibromatosis type 1 is crucial for early detection, monitoring, and management, with the goal of improving patient outcomes and quality of life. […] Early detection and regular surveillance are paramount for effective management and reduction of cancer risk in neurofibromatosis type 1 patients.
#16 Neurofibromatosis Type 1 – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK459358/
The outlook for patients with NF-1 is guarded and depends on the severity of the disease, the presence of malignancy, and the extent of the deformity. Those with mild disease can have a reasonable life expectancy, but those with moderate to severe disease have a poor quality of life. […] Women with NF-1-related breast cancer have a poor 5-year survival rate and high mortality. […] Patients with central nervous system tumors are at increased risk for secondary malignancies, mortality, and vascular complications. […] Malignant peripheral nerve sheath tumors in association with NF-1 have poor overall survival. […] The primary contributing variable to mortality among patients with NF1 includes brain tumors and MPNSTs. […] Serial evaluation with WBMRI should be assessed based on the clinical and NF1 domains. […] The cohort of 2467 individuals from the Denmark RAREDIS Database from (1995-2013) was observed to have increased odds for the risk of hospitalizations, psychiatric illnesses, poor academic performances, poor relationship, abortions and stillbirths, poor quality of life, and increased dependency.
#17 Cancer Risk in Patients With Neurofibromatosis Type 1 – Diagnosis & Disease Information
https://www.cancertherapyadvisor.com/ddi/cancer-risk-in-patients-with-neurofibromatosis-type-1/
The prognosis for neurofibromatosis type 1 depends on the type and location of tumors, the presence of complications, and the development of malignant tumors. Although most people with neurofibromatosis type 1 have an average life expectancy, those who develop MPNSTs (8% to 13%) or other cancers face a more challenging prognosis. Malignant peripheral nerve sheath tumors are aggressive and patients who develop them have a 5-year survival rate of approximately 44% to 55%. Early detection and treatment of these malignancies are critical for improving outcomes. Other factors affecting the prognosis include the presence of cognitive impairments, skeletal abnormalities, and other complications related to neurofibromatosis type 1. […] Understanding the cancer risk of patients with neurofibromatosis type 1 is crucial for early detection, monitoring, and management, with the goal of improving patient outcomes and quality of life. […] Early detection and regular surveillance are paramount for effective management and reduction of cancer risk in neurofibromatosis type 1 patients.
#18 Genes | An Open Access Journal from MDPI
https://www.mdpi.com/journal/genes
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder caused by mutations in the NF1 gene, typically diagnosed during early childhood and characterized by significant phenotypic heterogeneity. […] Despite advancements in next-generation sequencing (NGS), the diagnostic process remains challenging due to the geneâs complexity, high mutational burden, and frequent identification of variants of uncertain significance (VUS). This review explores the emerging role of artificial intelligence (AI) in enhancing NF1 variant detection, classification, and interpretation. […] The integration of AI methodologies offers substantial potential to improve diagnostic precision, enable early intervention, and support personalized medicine approaches. However, key challenges remain, including algorithmic bias, limited data diversity, and the need for functional validation. Ongoing refinement and clinical validation of these tools are essential to ensure their effective implementation and equitable use in NF1 diagnostics.
#19 Genes | An Open Access Journal from MDPI
https://www.mdpi.com/journal/genes
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder caused by mutations in the NF1 gene, typically diagnosed during early childhood and characterized by significant phenotypic heterogeneity. […] Despite advancements in next-generation sequencing (NGS), the diagnostic process remains challenging due to the geneâs complexity, high mutational burden, and frequent identification of variants of uncertain significance (VUS). This review explores the emerging role of artificial intelligence (AI) in enhancing NF1 variant detection, classification, and interpretation. […] The integration of AI methodologies offers substantial potential to improve diagnostic precision, enable early intervention, and support personalized medicine approaches. However, key challenges remain, including algorithmic bias, limited data diversity, and the need for functional validation. Ongoing refinement and clinical validation of these tools are essential to ensure their effective implementation and equitable use in NF1 diagnostics.
#20 Cancer Risk in Patients With Neurofibromatosis Type 1 – Diagnosis & Disease Information
https://www.cancertherapyadvisor.com/ddi/cancer-risk-in-patients-with-neurofibromatosis-type-1/
The prognosis for neurofibromatosis type 1 depends on the type and location of tumors, the presence of complications, and the development of malignant tumors. Although most people with neurofibromatosis type 1 have an average life expectancy, those who develop MPNSTs (8% to 13%) or other cancers face a more challenging prognosis. Malignant peripheral nerve sheath tumors are aggressive and patients who develop them have a 5-year survival rate of approximately 44% to 55%. Early detection and treatment of these malignancies are critical for improving outcomes. Other factors affecting the prognosis include the presence of cognitive impairments, skeletal abnormalities, and other complications related to neurofibromatosis type 1. […] Understanding the cancer risk of patients with neurofibromatosis type 1 is crucial for early detection, monitoring, and management, with the goal of improving patient outcomes and quality of life. […] Early detection and regular surveillance are paramount for effective management and reduction of cancer risk in neurofibromatosis type 1 patients.
#21 Neurofibromatosis Type 1 – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK459358/
The outlook for patients with NF-1 is guarded and depends on the severity of the disease, the presence of malignancy, and the extent of the deformity. Those with mild disease can have a reasonable life expectancy, but those with moderate to severe disease have a poor quality of life. […] Women with NF-1-related breast cancer have a poor 5-year survival rate and high mortality. […] Patients with central nervous system tumors are at increased risk for secondary malignancies, mortality, and vascular complications. […] Malignant peripheral nerve sheath tumors in association with NF-1 have poor overall survival. […] The primary contributing variable to mortality among patients with NF1 includes brain tumors and MPNSTs. […] Serial evaluation with WBMRI should be assessed based on the clinical and NF1 domains. […] The cohort of 2467 individuals from the Denmark RAREDIS Database from (1995-2013) was observed to have increased odds for the risk of hospitalizations, psychiatric illnesses, poor academic performances, poor relationship, abortions and stillbirths, poor quality of life, and increased dependency.
#22 Cancer Risk in Patients With Neurofibromatosis Type 1 – Diagnosis & Disease Information
https://www.cancertherapyadvisor.com/ddi/cancer-risk-in-patients-with-neurofibromatosis-type-1/
The prognosis for neurofibromatosis type 1 depends on the type and location of tumors, the presence of complications, and the development of malignant tumors. Although most people with neurofibromatosis type 1 have an average life expectancy, those who develop MPNSTs (8% to 13%) or other cancers face a more challenging prognosis. Malignant peripheral nerve sheath tumors are aggressive and patients who develop them have a 5-year survival rate of approximately 44% to 55%. Early detection and treatment of these malignancies are critical for improving outcomes. Other factors affecting the prognosis include the presence of cognitive impairments, skeletal abnormalities, and other complications related to neurofibromatosis type 1. […] Understanding the cancer risk of patients with neurofibromatosis type 1 is crucial for early detection, monitoring, and management, with the goal of improving patient outcomes and quality of life. […] Early detection and regular surveillance are paramount for effective management and reduction of cancer risk in neurofibromatosis type 1 patients.